SASCHA ROTH FIGURED THAT WHEN have cancer in your colon and lymph nodes and your oncologist calls you after business hours, two days before you're scheduled to begin a brutal five-week course of radiation therapy, it's probably not good news-especially when the first thing she says is, "Are you sitting down?"
Roth was the first patient that enrolled into a clinical trial to test a new immunotherapy drug, designed to unleash the body's natural immune response on the tumor cells, on patients with early stage cancers. The results were miraculous: One hundred percent of the patients went into total remission-perhaps the first time that's ever happened in any cancer clinical trial, according to Luis Diaz, head of the division of solid tumor oncology in Memorial Sloan Kettering's Department of Medicine and a designer of the trial. The trial suggested the new therapies, if delivered early enough, might not only obviate the need for traditional therapies notorious for their brutal side effects, like chemo, radiation and surgery. They could potentially cure the disease altogether.
Roth's doctor was jubilant: "We've reviewed all your scans, biopsies-everything," she says the doctor told her. "There is zero sign of cancer. We can't radiate you knowing there's no cancer in your body."
The trial, published last year in The New England Journal of Medicine, electrified the field of cancer research and held out the promise of a powerful new approach that might help relieve many people from the suffering and anxiety caused by a scourge that kills 610,000 people each year in the U.S.
هذه القصة مأخوذة من طبعة December 01 - 08, 2023 (Double Issue) من Newsweek US.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 8500 مجلة وصحيفة.
بالفعل مشترك ? تسجيل الدخول
هذه القصة مأخوذة من طبعة December 01 - 08, 2023 (Double Issue) من Newsweek US.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 8500 مجلة وصحيفة.
بالفعل مشترك? تسجيل الدخول
ARABIAIN MIGHT
SAUDI ARABIA'S INCREASING STRENGTH MEANS IT NOW HAS MUCH MORE CLOUT WITH ITS PARTNERS, INCLUDING THE U.S.
Bringing Trump's Trial to Life
Sketch artist Isabelle Brourman tells Newsweek what it was like covering the former president's court case
Iran Examines the Nuclear Option
Tehran's rhetoric could spark an arms race in the Middle East like never before
Climate Conviction at What Price?
Fifty years ago experts doubted Americans would pay to save the environment. Only some of their fears are still true
Most Loved Workplaces 2024
A THE WORLD'S MOST LOVED WORKPLACES ARE REMARKABLE FOR A variety of reasons.
Maya Hawke
MAYA HAWKE WEARS MANY HATS: ACTOR, WRITER, SINGER. BUT FOR Hawke, everything comes down to words.
Jacob Anderson
ANNE RICE'S NOVEL INTERVIEW WITH THE Vampire has a rabid fan base, intensely protective of the story and any adaptations of it.
VOTES OF NO CONFIDENCE
Why recent U.K. election results will ring alarm bells for Joe Biden
BIDEN'S BATTLEGROUND ELECTION
A small number of Democrats PROTESTING the president's support for Israel's war in Gaza could PREVENT him from winning a second term
'It's Time to Treat Addiction Like Cancer'
Both are serious illnesses but, unlike those struggling with substance use disorders, didn’t face shame and stigma when seeking help over my tumors